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Abstract 
UDP-glucose is an essential metabolite for a variety of processes in the cell physiology in all 
organisms. In prokaryotes, it is involved in the synthesis of trehalose, an osmoprotectant, in 
galactose utilization via the Leloir pathway and it plays a key role in the synthesis of the 
components of the bacterial envelope, particularly the lipopolysaccharide and the capsule, 
which represent necessary virulence factors of many bacterial pathogens. UDP-glucose is 
synthesized in bacteria by the prokaryotic UDP-glucose pyrophosphorylase (UGP, EC 2.7.7.9), 
an enzyme belonging to the family of sugar:nucleotidyl transferases. Despite the ubiquitous 
distribution of UGP activity in all domains of life, prokaryotic UGPs are evolutionarily 
unrelated to their eukaryotic counterparts. Taken together, these features make of bacterial UGP 
an attractive target candidate for the discovery and development of new generation antibiotics. 
This review summarizes the current knowledge on structure and function of bacterial UGPs, 
underlying their potential as drug target candidates. 
 
1. INTRODUCTION 
The last decades have witnessed an increasing interest in the study of carbohydrates and 
glycoconjugates, given the pivotal roles they play in a number of processes, including infection, 
fertility, cell size control, cell-cell and cell-matrix interactions, and many others, through their 
recognition by lectins [1] and other molecular receptors, such as antibodies [2] and 
carbohydrate-processing enzymes [3-4]. 
Glycosyl phosphoesters of nucleoside pyrophosphates, more often referred to as sugar-
nucleotides, occupy a relevant place in carbohydrate metabolism as the activated forms serving 
as glycosyl donors for the synthesis of complex carbohydrates and the sugar moieties of 
glycoconjugates. Of these, UDP-glucose is a highly multifunctional metabolite, being essential 
for a rich variety of processes and a crossroad point in carbohydrate metabolism. In animal and 
fungal metabolism, UDP-glucose is the sugar donor for glycogen synthesis and, as in all 
eukaryotes, in the formation of the carbohydrate moieties of glycolipids, glycoproteins and 
proteoglycans [5], and is required for galactose utilization [6]. In plants, UDP-glucose is used 
for the synthesis of sucrose and cellulose and is involved in starch metabolism [7]. In 
prokaryotes, perhaps, the most distinguishing role of UDP-glucose is its participation in the 
synthesis of different components of the bacterial envelope, particularly the lipopolysaccharide 
(LPS) and the capsule, structures that represent necessary virulence factors of many 
microorganisms. 
UTP:α-D-glucose-1-phosphate uridylyltransferase (EC 2.7.7.9), commonly referred to as UDP-
glucose pyrophosphorylase, and abbreviated as UGP or by the capitalization of its coding gene 
in E. coli (GalU), catalyzes the reversible formation of UDP-glucose and pyrophosphate (PPi) 
from glucose-1-phosphate and UTP (fig. 1). UGP activity is ubiquitous to all domains of life, 
given the functional importance of its product. However, and interestingly, prokaryotic UGPs 
are evolutionary unrelated to their eukaryotic counterparts [8].  
 
Figure 1: Enzymatic conversion catalyzed by UDP-glucose pyrophosphorylase. 
 
 
The aim of this review is to summarize the current knowledge on structure, activity and function 
of prokaryotic UGP, and a special emphasis in its potential use as an antimicrobial target is 
made. Comprehensive information on eukaryotic UGPs can be found elsewhere [7, 9]. 
 
2. A HISTORIC OVERVIEW 
In 1950, as part of their studies on galactose metabolism in yeast, L. F. Leloir and his co-
workers discovered a compound which was needed for a step of the reaction pathway now 
known as the Leloir pathway. Presence of uridine, phosphate and glucose in this compound, as 
well as the correct linkage of the different components were ascertained, thus identifying it as 
UDP-glucose, the first sugar nucleotide to be discovered, and described as a «coenzyme of the 
galactose phosphate-glucose phosphate transformation» [10]. Later, Kalckar et al. detected 
UDPG:PP activity in yeast samples [11]. Specifically, they found out that dialyzed yeast 
maceration juice, when in the presence of UDP-glucose, promoted the formation of inorganic 
pyrophosphate and UTP, hence discovering the reverse reaction. As a result, the newly 
discovered enzyme adopted the name of “UDP-glucose pyrophosphorylase” (UGP), a 
denomination which has prevailed ever since, although the name “UTP:glucose-1-P 
uridilyltransferase” is also widely used. In addition, other authors have historically employed 
different denominations, such as “UDP-glucose synthetase”, coined by Sundararajan et al. in the 
early 1960s to stress the biosynthetic role of this enzyme [12]. 
The importance of UGP activity in bacterial biochemical pathways was soon realized, while 
further investigations during the genomic era brought to the realization that no phylogenetic 
relation existed between the prokaryotic enzyme and its counterpart of eukaryotic species [13]. 
This prompted interest in targeting bacterial UGP, as a means of disrupting a key enzymatic 
activity of prokaryotic pathogens without disrupting the host metabolism. With this objective in 
mind, several research groups provided crystallographic structures of UGPs from different 
bacterial sources [14-17]. 
 
3. PHYLOGENETIC CONTEXT 
UDP-glucose phosphorylase belongs to the superfamily of the NTP:sugar 
nucleotidyltransferases (nucleoside diphosphate sugar pyrophosphorylases), a related group of 
proteins that exhibit a similar folding [17] and certain conserved sequence elements, most 
notably the N-terminal motif GXGTRXLPXT [18], carrying a putative catalytic arginine 
residue [17, 19]. Apart from the mentioned features, it is characteristic of bacterial UGPs the 
presence of the signature motif VEKP, which carries essential residues involved in interaction 
with the glucosyl part of its substrates [15, 17] (fig. 2). 
 
 Figure 2: ClustalX (v. 2.0.12) multiple sequence alignment of UGPs of selected prokaryotic organisms. The 
alignment shows the great conservation of the UGP sequence throughout the prokaryotic lineage. The E. coli GalF 
regulatory subunit still keeps a high degree of conservation, but with a catalytic arginine residue in helix α1 which is 
necessary for UGP activity being replaced by a histidine. 
 
Given its essential activity for the cell metabolism, UDP-glucose pyrophosphorylases are 
ubiquitously distributed throughout all domains of life. UGPs are, in addition, very well 
conserved proteins: for instance, the sequence of the Escherichia coli UGP bears a 29% identity 
with that from the archean Sulfolobus, and the human and barley enzymes share a 55% identity. 
However, and interestingly, sequence similarities between UGPs of prokaryotic origin and their 
eukaryotic counterparts lie around 8%, which is considered non-significant. For comparison, 
human UDP-galactose-4-epimerase, another enzyme rendering UDP-glucose as product, shares 
an identity of 51% with its E. coli homologue [20]. Thus, the UGPs of prokaryotic and of 
eukaryotic origin are believed to be evolutionarily unrelated [8, 17]. Fittingly, Hartman and 
Fedorov classified the eukaryotic UGP as a “eukaryotic signature protein”, being itself one of 
only a handful enzymes in a list of 347 proteins that were considered to be genuine eukaryotic 
inventions [13]. 
In light of this data, a number of authors have underlined the attractiveness of bacterial UGPs as 
potential antimicrobial targets, as a means of selectively inhibit the pathogen enzyme without 
disrupting the host metabolism [8, 17, 21]. 
Nonetheless, eukaryotic organisms do posses other nucleotidyltransferases sharing certain 
homology with the members of the bacterial superfamily, notably the eukaryotic GDP-mannose 
pyrophosphorylases (GMPPs) (fig. 3), but also plant sucrose synthase (SuSy, which in fact 
employs UDP-glucose as a substrate, too) and others [9]. 
Interestingly, bacterial UGPs share some sequence similarity with some other eukaryotic 
proteins not involved in sugar metabolism. In eukaryotic genomes, the sequences most similar 
to those of prokaryotic UGP and GMPPs, belong to the γ-subunit of the eukaryotic translation 
initiation factor eIF2B (fig. 3), a multisubunit complex that is required for protein 
synthesis initiation and its regulation in eukaryotic cells. The eIF2B-γ subunit binds GTP [22] 
and it shows, in fact, a strong sequence similarity with GMPPs, suggesting that evolution might 
have taken advantage of the binding capabilities of a hypothetical ancestor related to GMPPs to 
tailor this protein.  
 
 Figure 3: Dendrogram showing phylogenetic relations of a selection of prokaryotic and eukaryotic UGPs, eukaryotic 
GTP-mannose pyrophosphorylases, members of the Arabidopsis sucrose synthase (SuSy) family and the gamma 
subunit of the human eukaryotic initiation factor 2B (eIF2B-γ). A multiple sequence alignment was generated with 
ClustalW (http://www.genome.jp/tools/clustalw/) using the BLOSUM matrix. An asterisk indicates the position of 
the non-catalytic GalF protein from E. coli. 
 
In short, prokaryotic UGPs belong to a cluster of phylogenetically related proteins, which 
include the eukaryotic eIF2B-γ and GMP, but not the eukaryotic UGP. In spite of the 
phylogenetic relations between bacterial UGPs and the latter eukaryotic proteins, the lack of 
homologous eukaryotic protein acting on the same substrates gives support to the attractiveness 
of bacterial UGPs as novel target candidates. 
 
4. STRUCTURE AND MECHANISM OF ACTION 
Up to date, crystallographic structures of four bacterial UGPs have been reported, specifically 
those from E. coli (PDB code: 2E3D) [14], Corynebacterium glutamicum (PDB code: 2PA4) 
[15], Sphingomonas elodea (PDB code: 2UX8) [16] and Helicobacter pylori (PDB code 3JUJ 
and 3JUK) [17], all of which share a very similar structure. Here, the structure of the H. pylori 
enzyme is discussed as representative of the group. 
 4.1. Overall structure 
All four UGP structures were crystallized as tetramers (fig. 4). Each monomer, of approximately 
30-35 kDa, presents a characteristic folding, dominated by a central mixed β-sheet, reminiscent 
of the nucleotide-binding Rossmann fold, but including nine β-strands, surrounded by eleven α-
helices and two additional β-strands (fig 5). The overall quaternary structure can be understood 
as a dimer of dimers, with ‘tight’ dimers resulting of extensive interactions established between 
two adjacent subunits, and ‘loose’ dimers arisen from weaker packing interactions between the 
alternate pairs of subunits (fig. 4). In the H. pylori UGP, the ‘tight’ dimers result from 
interactions made by residues located mainly in the α1, α4 and α12 helices and the α2-α3 loop, 
between subunits A and B, and C and D, respectively. In other UGPs (e.g. that of S. elodea), an 
additional helix exists at the C-terminus, which gives rise, together with the preceding helix, to 
a V-shaped domain that further stabilizes the dimer by interacting with its homologous in the 
other monomer. The ‘loose’ dimers arise from contacts between the 3 strands from each 
alternate subunit A and C, and B and D, respectively. 
A very similar folding in the monomers is found in other NDP:sugar pyrophosphorylases [19, 
23-25], even though the amino acid sequence homology among the members of this family is 
often very small, or none. By contrast, the quaternary structure greatly varies within the family, 
existing trimers (N-acetylglucosamine-1-P uridylyltransferases [26]), hexamers (glucose-1-P 
cytidylyltransferases [24]), homodimers (GDP-mannose pyrophosphorylases [25]) and 
heterodimers (plant ADP-glucose pyrophosphorylases [23]), among other forms of arrangement. 
 
4.2. Active center 
As in other pyrophosphorylases, such as thymidylyltransferases, each bacterial UGP subunit 
carries on an active site made up by residues located in the same polypeptide chain [19]. This is 
in contrast with cytidylyltransferases, in which active sites are formed by residues located in 
different subunits [15]. In UGPs, the active center is located in a deep cleft delimited by 1, 4, 
8, α9, α7, α11 and nearby loops (fig. 5). Residues involved in binding and catalysis are 
extremely conserved among UGPs of different species. These residues are located mainly in 
loops facing the active site cleft, rather than in the neighboring α-helices or -strands. 
 
 Figure 4: Tetrameric structure of H. pylori UGP 
(PDB code: 3JUK) [17]. Subunits A and C 
(secondary structure ribbon representation ) and B 
and D (solvent accesibility surface representation). 
Subunit pairs A/B and C/D  interact within a region 
including three α-helices (α-4 and α-12 are 
highlighted in subunits A and C)  and a loop between 
α-2 and α-3 (highlighted in A), forming the 
respective ‘tight dimers’. In addition, subunits A and 
D, and B and C are packed, in a weaker manner, with 
participation of residues located in their respective β-
3 strands.  
 
 
Figure 5: H. pylori UGPase in its apo form (PDB 
code: 3JUJ), with labels indicating the identity of the 
individual alpha helices and beta strands. 
 
 
The available crystal structures of prokaryotic UGPs include the apo-enzyme (3JUJ, 2E3D), the 
binary complex UGP/UDP-glucose (3JUK) and the binary complex UGP/UTP (2UX8). In all 
cases, the tertiary structure of the enzyme, and the interactions that it establishes with the 
nucleotide moiety of the substrates are essentially similar. Fig. 6 shows UDP-glucose anchored 
to the H. pylori UGPase active site, showing key contacts between the enzyme atoms and those 
of its product. In the bound state, both the nucleoside and sugar moieties are buried inside the 
active site pocket, unlike the phosphate groups, which remain fully accessible to the solvent. 
The nucleoside moiety of UDP-glucose interacts with the Ala10 and Gly11 backbone NHs from 
the conserved N-terminal motif, at the level of the O2 and O2’ atoms, respectively. In addition, 
the Gln102 ε-amide and the Gly107 NH interact with O4 of the uracyl. Negatively charged 
phosphate groups are docked to the enzyme by electrostatic interactions with a pair of conserved 
lysine residues. The first phosphate interacts with the Lys191 side-chain from the VEKP 
signature motif, whereas the second phosphate contacts the Lys25 side-chain. Two phosphoryl 
oxygens from the phosphate pair are coordinated with a Mg2+ ion, whose coordination sphere is 
completed by the Glu130 carboxylate and three ordered water molecules. Gly171 can hydrogen-
bond to any of both the 3’- and 4’-hydroxyl groups of the glucose moiety, Asp131 contacts the 
6’-hydroxyl group, and Glu190 carboxyl oxygens from the VEKP motif interact with the sugar 
2’ and 3’-hydroxyl groups, a bidentate interaction commonly found in other glucose-protein 
interactions, such as those found in lectins [27]. Finally, a conserved arginine residue (Arg15) is 
located apart from the ligand and is not involved in binding, since mutation of this residue has 
no significant effects on the affinity of the enzyme towards its substrates [17]. Instead, it plays 
an important role in the catalytic activity. 
 
 
Figure 6: Diagram of the H. pylori UGP active center, in complex with UDP-glucose [17]. The protein 
residues participating in substrate binding are depicted in yellow, and a magnesium ion, coordinated with 
Glu130, two phosphoryl groups and three water molecules, is shown in green. Black dotted lines 
represent the inferred interactions implicated in substrate binding.  
 
4.3. Specificity 
The specificity of UGP for its substrates is determined by the architecture of its active site. 
Substrates incorporating sugars other than lactose are not processed by this enzyme. Galactose 
binding, although sterically possible, is less favored than glucose binding by the loss of a 
hydrogen bond with Gly171. Binding of purine bases is sterically impeded by residues from 3, 
7 and loops 1- 1 and 3- 7. Cytosine binding is prevented by the lack of specific hydrogen 
bonds [17]. However, promiscuity towards dTTP has been documented for UGPases from 
different sources, such as Salmonella enterica [28], S. elodea and E. coli [29-30], while the 
enzyme from other organisms, like H. pylori [17], has been shown to be strictly specific to 
uracyl nucleotides. In the H. pylori UGP, accommodation of thymine instead of uracyl is 
impeded because of steric clashes between the extra methyl group of thymine and the bulky 
Met105 side-chain on the 3- 4 loop. In the S. elodea enzyme, however, this methionine is 
changed to a proline (Pro108), leaving enough space for a thymine base. Similarly, an alanine 
occupies the same position in the E. coli enzyme (fig. 2), which could account for its 
promiscuity towards dTTP. Being the residues within this loop less conserved than other 
sequence elements (fig. 2), this region could be differently sculpted, depending on the 
organism’s requirements, to acquire the desired specificity. 
 
4.4. Reaction mechanism 
The catalytic mechanism followed by NDP-sugar pyrophosphorylases has historically been a 
subject of controversy. Early insights into the mode of action of a member of the family 
suggested a sequential ordered Bi-Bi mechanism, in which the substrates enter the active site in 
an orderly fashion, react, and depart from the enzyme in a precise order. Nonetheless, it was 
speculated that the phosphorolysis reaction could operate also through a ping-pong mechanism, 
via a covalent intermediate between the nucleotide and the enzyme [31], a possibility that was 
discarded by the absence of 14C incorporation to the enzyme from the labelled sugar-phosphate. 
Speculation persisted, nonetheless, if the second substrate binds and simultaneously reacts (the 
so-called ‘hit and run’ mechanism) or binds, and then reacts [19]. 
Isothermal titration calorimetry (ITC) measurements, together with crystallographic data for a 
number of pyrophosphorylases [17, 19], including UGP, point to a sequential ordered Bi-Bi 
catalytic mechanism, in which the nucleoside triphosphate binds to the enzyme first, followed 
by the sugar-phosphate binding to the enzyme/nucleotide complex. 
In UDP-glucose pyrophosphorylases, the reaction is initiated by a nucleophilic attack of the 
glucose-1-P phosphoryl oxygen on the phosphorous atom of the UTP α-phosphate. It is thought 
that a Mg2+ ion participates in the catalysis by both stabilizing the excess of negative charge and 
properly positioning the phosphoryl oxygen of glucose-1-phosphate for its nucleophilic attack 
[32]. Indeed, the presence of magnesium has been shown to be absolutely required for the 
catalysis [33], as well as enhancing the binding affinity of UGP towards UTP and UDP-glucose 
[17]. After the reaction takes place, the β- and γ-phosphates are displaced and leave the 
enzyme/UDP-glucose complex as inorganic pyrophosphate, followed by dissociation of UDP-
glucose (Fig. 7). In the reverse reaction, pyrophosphate nucleophilically attacks UDP-glucose 
and glucose-1-P is displaced, followed by release of UTP. 
Kinetic parameters for UGP of different prokaryotic sources are available, showing some 
variation among species. In E. coli, Michaelis-Menten constant (KM) values calculated are 0.71 
mM for UDP-Glc, 0.53 mM for PPi, 0.15 mM for Glc-1-P, and 0.23 for UTP [34], which are 
similar to the calculated KM values for the S. pneumoniae enzyme: 0.40 mM for UDP-Glc, 0.26 
mM for PPi, 0.19 mM for Glc-1-P, and 0.24 for UTP [33]. In contrast, the UGP of 
Sphingomonas paucimobilis shows a very low KM value for UDP-Glc (7.5 μM) [18], whereas 
the Acetobacter xylinum enzyme shows a higher KM value of 3.2 mM [35]. 
Catalyst rate constant (kcat) values are usually higher for UDP-Glc formation, from 40 s
-1 in 
Xanthomonas [36] to 148 s-1 in Streptomyces coelicolor [37], than for UDP-Glc 
pyrophosphorolysis (0.55 s-1 and 5.7 s-1 in Streptomyces and Xhantomonas, respectively). As 
can be inferred, enzyme efficiencies, calculated as kcat/KM, are higher for UDP-Glc synthesis 
than UDP-Glc pyrophosphorolysis. 
 
 
Figure 7: Scheme of the reaction mechanism for the synthesis of UDP-glucose followed by prokaryotic 
UGPs. 
 
 
 
5. FUNCTION AND REGULATION 
The relevance of UGPs for bacterial cell physiology is determined by the pivotal role of its 
product UDP-glucose in the bacterial metabolic pathways (Fig. 8). Occupying this central 
position in the bacterial metabolism, UDP-glucose serves both as a signaling molecule and as a 
building block for the synthesis of complex polysaccharide structures. As noted above, one of 
the main functions of UDP-glucose, in prokaryotes is to serve as glucosyl donor for 
carbohydrate biosynthesis. UDP-glucose is required for the synthesis of LPS, cell wall sugar 
moieties, capsular polysaccharides and membrane-derived oligosaccharides, as well as 
exopolysaccharides, either directly or via UDP-galactose. In addition, production of UDP-
glucose has been linked with osmotolerance and the complex coordination of cell size and the 
control of the bacterial cell cycle. 
 
 
Figure 8: Diagram showing the central position of UDP-glucose in the bacterial biochemical pathways. 
Arrows indicate the enzymatic transformations of UDP-glucose into several metabolites in E. coli, 
catalyzed by enzymes denoted by codes in gray. Gray ovals represent bacterial functions associated with 
those enzymatic activities. These functions, especially the presence of capsule and/or LPS in the bacterial 
envelope, are related with bacterial virulence (represented by a black oval). 
 
5.1. UDP-glucuronate synthesis 
UDP-glucose is a substrate of UDP-glucose-6-dehydrogenase (product of the ugd gene), which 
catalyzes the conversion of UDP-glucose into UDP-glucuronic acid. This sugar nucleotide is an 
important component of many bacterial virulence factors. In many gram negative bacteria, 
UDP-glucuronate is a precursor for the synthesis of the O-antigen, an important component of 
the lipopolysaccharide (LPS). In some gram-positive bacteria, such as Streptococcus 
pneumoniae, UDP-glucuronate is used as a donor for the addition of glucuronic acid to the 
capsular polysaccharide, considered an essential virulence factor of this microorganism [38-39]. 
Furthermore, in certain organisms, UDP-glucuronic acid is a precursor of UDP-4-amino-4-
deoxy-L-arabinose (UDP-Ara4N), which is utilized for the incorporation of Ara4N to lipid A of 
virulent strains of prominence, such as Pseudomonas isolated from cystic fibrosis patients [40]. 
This modification is a well-known defense mechanism against cationic antimicrobial peptides 
[41]. 
 
5.2. Galactose metabolism 
In most bacteria, UDP-glucose is required for the utilization of galactose, via the Leloir pathway 
[42]. In the first step of this pathway, β-D-galactose is epimerized to α-D-galactose by action of 
galactose mutarotase. Then, α-D-galactose is phosphorylated in position 1 by galactokinase, 
consuming ATP. Next, UDP is transferred from UDP-glucose to galactose-1-P by action of 
galactose-1-P uridyltransferase (galT), hereby generating UDP-galactose and glucose-1-P. 
UDP-galactose yields back UDP-glucose by action of UDP-galactose-4’-epimerase (galE). This 
means of transforming β-D-galactose into the more metabolically useful glucose derivatives 
permits organisms using this pathway to develop in cultures with galactose as the sole source of 
carbon, and bacteria lacking any of the implicated enzymes fail to grow in such media [43]. 
Similarly, defects in the human genes coding for enzymes of this pathway lead to a pathology 
known collectively as galactosemia [44]. Importantly, as UDP-glucose is involved in the 
pathway, UGP defective strains are unable to utilize galactose as a carbon and energy source.  
In addition, UDP-galactose and UDP-galacturonate are utilized as sugar donors of galactose and 
galacturonate, respectively, for the synthesis of complex bacterial polysaccharides, such as the 
LPS and the gram-positive capsule polysaccharide [45-46]. This way, the lack of UGP activity 
shows detrimental effects for the synthesis of these bacterial structures, not only directly at the 
level of its glucose and glucuronic units, but also indirectly on the incorporation of galactose 
and galacturonic acid. In S. pneumoniae, at least one of these four sugars is present in the 
capsule of all virulent serotypes [47]. 
 
5.3. Trehalose synthesis and response to stress 
In most bacterial organisms, UDP-glucose is a precursor of trehalose, a dissacharide composed 
of two glucose units linked in an α,α-1,1-glycosidic linkage. The most widely found 
biosynthetic pathway for trehalose synthesis involves the transfer of glucose from UDP-glucose 
to glucose-6-phosphate to form trehalose-6-P, a reaction catalyzed by trehalose-P synthase 
(coded by otsA gene in E. coli), followed by trehalose-6-P to trehalose conversion by trehalose-
P phosphatase (coded by otsB gene in E. coli) [48]. The so-obtained trehalose can be utilized in 
bacteria as a protectant and stabilizer of proteins and membranes upon a variety of stressful 
conditions. Trehalose confers bacterial resistance to desiccation [34-35], through inhibition of 
lipid fusion and phase transition of lipid bilayers occurring upon dehydration [48]. It also 
protects the bacterial cell against cold: an E. coli strain defective in the trehalose synthesis died 
much faster at 4 ºC, and its susceptibility was reverted after transformation with otsA/otsB; it 
was also shown that trehalose content in the bacterial cell increased eight-fold after exposure to 
16 ºC of cultures maintained at 37 ºC [49]. In addition, trehalose is a well-known 
osmoprotectant metabolite in E. coli and other bacteria, and its accumulation in the prokaryotic 
cell in response to salt stress has been documented [50-51]; notably, trehalose is synthesized at 
high levels in cells of Desulfohalobium retbaense, a microorganism able to grow in media 
containing NaCl concentrations up to 24 % [52]. E. coli strains defective in UGP are unable to 
synthesize trehalose and become osmotically sensitive [53].  
Interestingly, some data suggest that the protective effects of trehalose might be elicited by 
UDP-glucose itself, acting as an intracellular signaling metabolite. In E. coli cells, galU 
mutation caused overexpression of the σS subunit of RNA polymerase, a factor which is 
involved in response to stress through the regulation of σS-dependent genes, which include otsA 
and otsB [54].  
In addition to its protectant role, some organisms, such as mycobacteria and corynebacteria, 
incorporate trehalose as a structural component of their cell wall [48]. Importantly, the M. 
tuberculosis cell wall contains trehalose-dimycolate, a glycolipid composed of the fatty acid 
mycolic acid, esterified to the 6-hydroxyl group of both glucose units of trehalose. This 
glycolipid is considered among the major toxic components of the mycobacterial envelope, and 
a factor favoring its low permeability, a cause for the ample resistance of M. tuberculosis to 
many known antibiotics [55]. 
 
5.4. Coupling cell size with nutrient availability 
Recently, the participation of UDP-glucose as a sensing molecule involved in the control of the 
complex coordination that regulates cell size and division has begun to be unveiled in 
Escherichia coli [56]. As an intracellular proxy for nutrient status, UDP-glucose links nutrient 
availability with cell division. Nutrient-rich media permit UDP-glucose activation of OpgH, an 
inner-membrane glycosyltransferase involved in the biogenesis of the bacterial envelope, 
leading to the inhibition of FtsZ ring formation. Direct protein-protein interaction with FtsZ by 
the N-terminus domain of OpgH is dependent of UDP-glucose, endowing this 
glycosyltranferase with an inhibitory role on cell division. In addition, OpgH governs the 
synthesis of osmoregulated periplasmic glucans (OPG), a family of polyglucose backbones 
which are important components of the envelope of gram negative bacteria that play a role in 
their interaction with eukaryotic hosts [57] OPGs are linear β(1→2)glucose polymers with 
β(1→6) branches, that can be further modified with phosphoglycerol, phosphoethanolamine and 
succinic esther. In many proteobacteria, such as Erwinia and Pseudomonas, they are involved in 
osmoprotection, biofilm formation and resistance to antibiotics [58]. Nevertheless, the 
regulation of cell size by OpgH is independent of its role in OPG synthesis.  
 
5.5. GalF: a regulatory subunit? 
The function of UGPs of some organisms has been reported to be modulated by the protein 
encoded by the gene galF. This gene was found immediately upstream to the operon rfb, which 
codes for proteins involved in the biosynthesis of the sugar-nucleotide dTDP-rhamnose in E. 
coli. The galF gene product showed high sequence homology with that of galU, in such way 
that both genes were thought to code for isoenzymes [59]. However, Marolda and Valvano 
demonstrated the lack of UGP activity of the galF gene product, GalF, and showed that GalF 
and UGP physically interacted in vivo. GalF-UGP interaction was shown to decrease the rate of 
phosphorolysis, thus maintaining UDP-glucose levels high. Furthermore, in the same study, 
they found that GalF binding enhanced UGP thermostability. The authors concluded that GalF 
might be a modulating, non-catalytic subunit of the UGP complex in vivo [60]. Since the 
tetrameric nature of the complex in vivo is generally well accepted, it is conceivable that UGP, 
jointly with GalF, could be active in the form of heterotetramers in the bacterial cell of GalF-
having organisms. 
The absence of pyrophosphorylase activity in GalF is likely due to mutation of critical amino 
acids, despite a very well-conserved primary sequence homology with UGP. Notably, the 
catalytic arginine in UGP is substituted by a histidine in GalF (fig. 2). 
Most bacterial groups lack GalF homologues, being it apparently restricted to enterobacteria. In 
fact, enterobacterial GalF sequences aligned with those of UPG of various organisms cluster 
with enterobacterial UPGs sequences, indicating that GalF originated in a recent divergence 
within this group (fig. 3). In addition, GalF seems not to be absolutely required for cell viability, 
nor it is absolutely required for normal UGP activity in vivo, as galF mutation did not affect 
growth and the LPS profile in Yersinia [61]. In any case, considerable investigation is still 
needed to elucidate the precise role of GalF on the modulation of the UGP activity. 
 
6. VALUE AS A THERAPEUTIC TARGET 
 
The central position of UDP-glucose in the bacterial biochemical pathways, very prominently 
those involved in the synthesis of envelope structures, determines that strains defective for this 
enzyme show markedly impaired pathogenic phenotypes. Not unexpectedly, the gene galU can 
be found as an essential gene for one third of all bacteria taxa included in the database of 
essential genes [62]. 
In S. pneumoniae, at least 90 capsular types have been described [63], and the organization of 
the gene cluster responsible for the biosynthesis of several capsular types has been analyzed [47, 
63-64]. UDP-glucose is needed for the addition of glucose, galactose (via the epimerization of 
the activated sugar), glucuronic and galacturonic acid residues of the pneumococcal capsule. 
Since at least one of these four sugars is found in all capsular polysaccharides, pharmacological 
inhibition of UGP would affect the biosynthesis of the pneumococcal capsule, considered a sine 
qua non component of pathogenicity of this microorganism [21, 33]. Figure 9C shows the 
unencapsulated phenotype of galU defective pneumococci, which is correlated with its 
apathogenicity.  
 
 
Figure 9: Capsule phenotypes for three pneumococcal strains: A: M23, B: M23c, and C: M23g (GalU), 
showing the unencapsulated phenotype of the galU mutant (C). Bar, 1 mm. Reproduced under the 
Creative Commons license. ©Mollerach et al., 1998. Originally published in J. Exp. Med., doi: 
10.1084/jem.188.11.2047. 
  
In addition to S. pneumoniae, it has been shown that galU mutation produces aberrant envelope 
structures in a large number of organisms. Consequently, the GalU UDPG:PP enzymatic 
activity may represent an important target in fighting bacterial infectious diseases [33]. In E. 
coli, such mutants were reported to produce incomplete LPS, containing only heptose and 3-
deoxy-D-manooctulosonic acid as sugar moieties. Moreover, these mutants showed motility 
impairment due to lack of functional flagella formation [65]. Loss of motility has been also 
shown to occur in other pathogenic organisms, such as Pseudomonas, upon galU mutation [66]. 
In addition, mutations in genes coding for UGPs have been shown to lead to decreased 
virulence of a number of diverse bacterial pathogens. In Klebsiella pulmoniae, galU mutation 
led to loss of mucoid colony phenotype and virulence in mice and high sensitiveness in human 
serum [67]. galU Vibrio colerae was defective in colonization and lost its capability to 
synthesize an exopolysaccharide biofilm involved in the formation of a resistant rugose variant 
[68]. Similarly, cornea infecting and systemic spreading capacities of Pseudomonas aeruginosa 
were impeded upon galU mutation [69], while the plant pathogen Xanthomonas citri was shown 
to require UGP activity for in planta growth and pathogenicity [70].  
Considering all above, and the tight control of nutrient availability, cell size, growth rate and 
central metabolism exerted by UDP-glucose, the advent of new molecules targeted against the 
activity of bacterial UGPs will obviously open new ways for broad applications in 
biotechnology and biomedicine. Specifically, inhibitors of this enzyme would be of great value 
for the treatment of diseases caused by pathogens that are resistant to the current therapeutic 
arsenal. Antimicrobial resistances to traditional drugs may take the global healthcare systems 
back to pre-antibiotic era in many aspects, making necessary a radical change of resource 
allocation and assessing interventions to research strategies that enable the identification of new 
targets. However, although pharma investments have been huge, it is surprising that the last 
decades of rational-based discovery have yet to be translated into a greater number of new 
medicines [71]. Rapid advances in Structural Biology, combined with Pharmacology, will not 
only enable the search for new targets, but also facilitate the study of existing targets for finding 
clues to new target identification and validation, and for probing the molecular mechanisms of 
drug actions and adverse reactions for both novel and existing drugs. Therefore, molecular 
understanding of protein-ligand binding will significantly impact and enhance Drug Discovery, 
from the in silico design to preclinical and clinical development.  
In this context, and although no inhibitors of prokaryotic UGPs have been reported to date, their 
promising profile as target candidates has been referred to by many authors, given its 
participation in key metabolic pathways and the synthesis of some of the most important 
bacterial virulence factors, together with the fact that there is no relation, aside from the 
catalytic activity, between bacterial UGPs and their eukaryotic counterparts. This last feature 
very well suits bacterial UGPs to provide the required specificity to avoid undesired toxicities, 
therefore possibly accelerating its development and speeding up its process to market. 
 
CONCLUDING REMARKS 
Antimicrobial resistance is not a recent phenomenon, but it constitutes a critical issue for 
healthcare systems worldwide. There is an urgent need to deeply investigate new alternatives to 
overcome the disease burden caused by infections. In this regard, bacterial UGPs are highly 
conserved enzymes which are involved in a number of key bacterial processes, including the 
synthesis of different elements of the bacterial envelope, considered necessary virulence factors 
of many pathogens.  
Detailed knowledge on the three-dimensional structure of UGPs at atomic scale, as well as their 
mechanism of action, are key to the process. Today, ample structural and mechanistic 
information is available to aid at drug discovery programs targeted to these enzymes. In 
addition, current understanding of the function of UGPs in the context of bacterial pathogenicity 
provides a sound base supporting a good perspective for potential drugs inhibiting UGPs. 
Taken together, all these characteristics make of bacterial UGPs an attractive target for 
alternative discovery programs and the potential development of new antibacterial agents with 
novel mechanisms of action. 
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